Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721127 | 1.00 | HCAR2 (0.50) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL30445761 | 0.81 | NNMT (0.44) | KDM4EVNN1LMNAPSMD14SMN1; SMN2 | |
| SCHEMBL1828070 | 0.81 | NNMT (0.44) | KDM4EVNN1LMNAPSMD14SMN1; SMN2 | |
| SCHEMBL8341810 | 0.79 | HCAR2 (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL21912461 | 0.79 | GABRP (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL487403 | 0.79 | KEAP1 (0.48) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL487554 | 0.79 | HCAR2 (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL487804 | 0.79 | HCAR2 (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL1608329 | 0.79 | HCAR2 (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E | |
| SCHEMBL114191 | 0.79 | HCAR2 (0.47) | HCAR2MGAMP4HA1P4HTMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| WO-2023049369-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| CN-103459386-B | N- (1,2, 5-oxadiazol-3-yl) pyridinecarboxamides and their use as herbicides | 拜耳知识产权有限责任公司 | 2016-06-22 | — | — | CN | disclosed |
| EP-2697208-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013074387-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| CN-102686572-A | Oxazoline derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| WO-2012096813-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012064569-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| CN-102076671-A | Triazole derivative or salt thereof | ASTELLAS PHARMA INC | 2011-05-25 | — | — | CN | disclosed |
| EP-1246802-A1 | 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | Dow Agrosciences LLC (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051468-A1 | 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | HCAR2 786/4885MGAM 4252/4885P4HA1 1846/4885 |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | HCAR2 1434/4885MGAM 4594/4885P4HA1 872/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | HCAR2 786/4885MGAM 4252/4885P4HA1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.